You are here
Regulated information
|
September 02, 2021
2021 HY Financial Report
|
|
September 02, 2021
bioMérieux - 2021 HY Financial Results
|
|
September 02, 2021
Notice of Publication of the 2021 HY Financial Report
|
|
September 02, 2020
Notice of Publication of the 2020 HY Financial Report
|
|
September 02, 2020
Interim Financial Report 2020
|
|
July 27, 2015
These information have been shifted to the Registration Document, now called Universal Registration Document
|
|
May 13, 2014
bioMérieux Rapport du Président 2013
|
|
April 22, 2013
Avis de mise à disposition du Rapport du Président du Conseil d'administration sur le contrôle interne
|
|
April 22, 2013
Report of the Chairman of the Board of Directors on Corporate Governance and Internal control report
|
|
April 30, 2010
Rapport sur le gouvernement d'entreprise et le contrôle interne 2009
|
|
July 27, 2015
These information have been shifted to the Registration Document, now called Universal Registration Document
|
|
May 13, 2014
bioMérieux Honoraires des commissaires aux comptes 2013
|
|
April 15, 2013
Honoraires des Commissaires aux Comptes 2012
|
|
April 28, 2010
Honoraires des Commissaires aux Comptes 2009 et 2008
|
|
June 11, 2009
Prospectus 2008
|
|
January 10, 2022
December 2021 - Declaration about number of shares issued and number of voting rights
|
|
December 08, 2021
November 2021 - Declaration about number of shares issued and number of voting rights
|
|
November 05, 2021
October 2021 - Declaration about number of shares issued and number of voting rights
|
|
October 08, 2021
September 2021 - Declaration about number of shares issued and number of voting rights
|
|
September 06, 2021
August 2021 - Declaration about number of shares issued and number of voting rights
|
|
October 10, 2013
Communiqué de mise à disposition du Prospectus Emission Obligataire visé par l'AMF Octobre 2013
|
|
May 07, 2004
Document de Base
|
|
January 06, 2022
French multidisciplinary consortium ARPEGE awarded public funding of close to €9 million to fight antibiotic resistance
|
|
December 14, 2021
Corporate Social Responsibility: bioMérieux recently received a series of official recognitions from independent third parties
|
|
December 10, 2021
bioMérieux – Increased outlook for full-year 2021
|
|
December 01, 2021
bioMérieux molecular tests efficiently detect SARS-CoV-2 Omicron variant
|
|
October 21, 2021
Baxter and bioMérieux announce CE mark for NEPHROCLEAR™ CCL14 test to predict persistent severe acute kidney injury
|
|
April 09, 2021
Notice of information related to preparatory documents for the Ordinary and Extraordinary Shareholders’ Meeting of May 20, 2021
|
|
May 22, 2020
Notice of information related to preparatory documents for the Ordinary and Extraordinary Shareholders’ Meeting of June 30, 2020
|
|
October 06, 2021
Disclosure of trading in own shares on September 30, 2021
|
|
July 07, 2021
Biannual report on bioMérieux's liquidity agreement as of June 30, 2021
|
|
May 20, 2021
AG 2021 - Description of share repurchase program
|
|
March 15, 2021
Disclosure of trading in own shares on March15, 2021
|
|
March 08, 2021
Disclosure of trading in own shares on March 8, 2021
|
No regulated information available